Jain Irrigation (JISLJALEQS)
TurnaroundScore breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹26.49 |
| Market Cap | ₹1,943.07 Cr |
| P/E Ratio | 50.97 |
| ROCE | 4.94% |
| ROE | 0.85% |
| Dividend Yield | 0% |
| Profit Growth | -297.45% |
| Debt/Equity | 0.72 |
| Sales Growth | -22.92% |
| Promoter Holding | 26.68% |
| 52-Week Range | ₹26.13 — ₹59 |
| Sector | Industrial Products |
| Book Value | ₹79.71 |
Strengths
- Price-to-book of 0.49—stock trades at a large discount to book value of ₹65.62
- Sales growth of 17.40% shows the business still has revenue momentum
- Debt-to-equity of 0.69 is moderate, not dangerously leveraged
- 52-week range of ₹26.40-₹59.00 suggests the stock is near the lower end, reducing speculative froth
Concerns
- Latest quarter net loss of ₹47 Cr and profit growth of -940.80% show severe earnings deterioration
- ROE of 0.85% and ROCE of 4.94% indicate very poor return on capital
- Promoter holding of only 26.68% is low and raises governance and alignment concerns
- Piotroski F-Score of 4/9 and FairStock Score of 4/100 point to financial weakness and high risk
AI Analysis
When I look at Jain Irrigation, the first thing I notice is that the market is valuing it at ₹32.26 against a book value of ₹65.62. That is a price-to-book of 0.49, so the market is deeply skeptical of the asset quality and earning power. And rightly so. The latest quarter shows a net loss of ₹47 Cr on sales of ₹1,598 Cr, while profit growth is a disastrous -940.80%. A company with ROE of just 0.85% and ROCE of 4.94% is not creating wealth for shareholders. As Graham would say, price is what you pay, value is what you get—but value here depends on whether the business can turn around. Sales growth of 17.40% is encouraging, but growth without profits is just expensive turnover. The P/E of 50.97 is meaningless with negative earnings, so I ignore it. The balance sheet is not terrible—debt-to-equity is 0.69—but the Piotroski F-Score of 4/9 signals financial distress. Promoter holding at 26.68% is low, which worries me because management's interests are not fully aligned with minority shareholders. There is no dividend, so the only return must come from recovery. This is not a quality compounder; it is a beaten-down business with an asset cushion. I would not buy today. I need evidence that the quarterly losses are narrowing, that sales growth is converting into positive net profit, and that return on capital is moving meaningfully above the cost of capital. Until then, this remains a turnaround candidate and a value trap risk.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer